Kidney Cancer Clinical Trial
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
18 years of age or older
Pathology-confirmed diagnosis of metastatic RCC
At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging
Written informed consent.
Specific inclusion criteria:
arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
arm 2: planned to be treated with non-ICI therapy
-Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Stanford California, 94305, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.